United States — Food and Drug Administration & Replimune Group

United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the resubmission of the Biologics License Application for RP1, setting a target action date and scheduling an advisory committee meeting, which are crucial steps in the regulatory process for Replimune Group's drug.

Replimune Group: The FDA's acceptance of the BLA resubmission for RP1 is a significant step towards potential accelerated approval, which could lead to increased revenue and market presence for Replimune Group. However, the stock price was down in pre-market trading, indicating some investor caution.

United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.

Replimune Group: Replimune is the defendant in multiple securities class actions and suffered a 38% stock price decline after the FDA rejected its BLA. The company faces potential financial damages and reputational harm.

United States — Food and Drug Administration: The FDA is the agency being led. It faces staff losses, morale issues, and policy controversies; Overton's nomination could exacerbate these challenges.

Replimune Group: Replimune Group, a biotech, had disagreements with the FDA under Makary. Overton's nomination may affect rare-disease drug approvals.

United States — Food and Drug Administration: The FDA will review the trial data for potential approval. The companies plan to file for approval, and the vaccine could be available as soon as 2027 if approved.

Replimune Group: Replimune's melanoma drug Tudriqev was recently approved, and the new vaccine may compete, but the overall market expansion could be positive.

United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.

Replimune Group: Replimune Group was mentioned in context of FDA scrutiny under Makary, but is not directly affected by this approval.

Replimune Group: Replimune Group is the target of multiple class action lawsuits due to alleged false statements regarding its IGNYTE trial, which led to the United States — Food and Drug Administration deeming the trial inadequate.

Replimune Group: Replimune Group>>> experienced rejection of its melanoma therapy by the United States — Food and Drug Administration>>> under Marty Makary>>>'s leadership, leading to public criticism and contributing to the pressure for his ouster.